Overview
- 9 inspections across 9 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2019-10-08.
At a glance
Inspections
9
Sites
9
Observations
1
Career since
May 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Astellas Pharma Inc. | 8 Oct 2019 | Human Drugs | On file |
| Novartis Pharma AG | 29 Aug 2019 | Human Drugs | On file |
| Amgen Manufacturing Limited LLC | 8 May 2019 | Human Drugs | On file |
| Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC | 18 Jan 2019 | Human Drugs | On file |
| Regeneron Pharmaceuticals, Inc. | 8 Jun 2018 | Human Drugs |
Sites inspected
Astellas Pharma Inc.Toyama, Japan1 insp.
Novartis Pharma AGBasel, Switzerland1 insp.
Amgen Manufacturing Limited LLCJuncos, United States1 insp.
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCAndover, United States1 insp.
Regeneron Pharmaceuticals, Inc.Rensselaer, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Wayne E Seifert1 shared
Marion Michaelis1 shared
Reyes Candau-Chacon1 shared
Ruth A Moore1 shared
Maria J Lopez- Barragan1 shared
Bo Chi1 shared
Diane L Raccasi1 shared
Full investigator report
Get the verbatim findings behind Maxwell L Van Tassell's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site